The CAR-T Revolution 3 Years After FDA Approval

Three years after FDA approval of the first CAR-T therapy, Stephan A. Grupp, MD, PhD; reviews outcomes data and provides an update on advancements and new trials in the field of cancer immunotherapy for patients with relapsed acute lymphoblastic leukemia (ALL). Richard Aplenc, MD, PhD, MSCE reviews current immunotherapeutic treatment options for pediatric acute myeloid leukemia (AML).

Related Centers and Programs: Cancer Immunotherapy Program